JP2024535380A5 - - Google Patents
Info
- Publication number
- JP2024535380A5 JP2024535380A5 JP2024518581A JP2024518581A JP2024535380A5 JP 2024535380 A5 JP2024535380 A5 JP 2024535380A5 JP 2024518581 A JP2024518581 A JP 2024518581A JP 2024518581 A JP2024518581 A JP 2024518581A JP 2024535380 A5 JP2024535380 A5 JP 2024535380A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- crystal
- compound
- crystals
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247774P | 2021-09-23 | 2021-09-23 | |
| US63/247,774 | 2021-09-23 | ||
| PCT/US2022/044475 WO2023049312A1 (en) | 2021-09-23 | 2022-09-23 | Egfr inhibitor polymorph forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535380A JP2024535380A (ja) | 2024-09-30 |
| JP2024535380A5 true JP2024535380A5 (https=) | 2025-09-29 |
Family
ID=85721153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518581A Pending JP2024535380A (ja) | 2021-09-23 | 2022-09-23 | Ｅｇｆｒ阻害剤の多形形態 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12545686B2 (https=) |
| EP (1) | EP4405360A4 (https=) |
| JP (1) | JP2024535380A (https=) |
| KR (1) | KR20250005041A (https=) |
| CN (1) | CN119343350A (https=) |
| AU (1) | AU2022350669A1 (https=) |
| CA (1) | CA3233057A1 (https=) |
| IL (1) | IL311616A (https=) |
| MX (1) | MX2024003495A (https=) |
| WO (1) | WO2023049312A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102809395B1 (ko) * | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| EP4405360A4 (en) | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHIC FORMS OF EGFR INHIBITOR |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| KR100397792B1 (ko) | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법 |
| EP1491211A4 (en) | 2002-03-29 | 2010-01-13 | Astellas Pharma Inc | DRUG AGAINST GLIOBLASTOMA |
| CN101219992B (zh) * | 2003-02-12 | 2011-08-31 | 日产化学工业株式会社 | 匹伐他汀钙的晶形 |
| EP1687308B1 (en) * | 2003-11-17 | 2019-06-12 | Merck & Cie | Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms |
| CN1854130B (zh) | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| EP1960552A2 (en) | 2005-12-16 | 2008-08-27 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
| JP2010501572A (ja) | 2006-08-22 | 2010-01-21 | コンサート ファーマシューティカルズ インコーポレイテッド | ４−アミノキナゾリン誘導体およびその使用方法 |
| WO2008046242A1 (fr) | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
| JP2008308491A (ja) | 2007-05-11 | 2008-12-25 | Gunma Univ | がん治療用の遊走阻害剤 |
| TW201019961A (en) | 2008-10-17 | 2010-06-01 | Genentech Inc | Combination therapy |
| WO2011035540A1 (zh) | 2009-09-28 | 2011-03-31 | 齐鲁制药有限公司 | 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物 |
| EA021439B1 (ru) | 2009-11-03 | 2015-06-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Хиназолиновые соединения |
| BRPI1003128A2 (pt) | 2010-08-06 | 2012-04-10 | Unicamp | processo de sìntese dos compostos meta e para-4-arilaminoquinazolìnicos para inibição da atividade tirosina-quinase do fator de crescimento epidérmico (egfrk) |
| ITPD20110091A1 (it) | 2011-03-24 | 2012-09-25 | Univ Padova | Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico. |
| WO2013013614A1 (zh) | 2011-07-28 | 2013-01-31 | 南京英派药业有限公司 | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 |
| CN103965211A (zh) | 2013-02-02 | 2014-08-06 | 江苏奥赛康药业股份有限公司 | 含喹唑啉结构的三环类衍生物及其制备方法和用途 |
| CN103965213A (zh) | 2013-02-02 | 2014-08-06 | 江苏奥赛康药业股份有限公司 | 7,8-二氢-6H-[1,4]噁嗪[3,2-g]喹唑啉类衍生物及其制备方法和用途 |
| CN103965212A (zh) | 2013-02-02 | 2014-08-06 | 江苏奥赛康药业股份有限公司 | 6,7,8,9-四氢-[1,4]氧氮杂卓[3,2-g]喹唑啉类衍生物及其制备方法和用途 |
| MX367772B (es) | 2013-04-04 | 2019-09-05 | Janssen Pharmaceutica Nv | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. |
| NZ732511A (en) * | 2014-12-15 | 2018-11-30 | Univ Michigan Regents | Small molecule inhibitors of egfr and pi3k |
| CA2974442A1 (en) | 2015-02-03 | 2016-08-11 | Trillium Therapeutics Inc. | Novel fluorinated derivatives as egfr inhibitors useful for treating cancers |
| HUE054065T2 (hu) | 2015-08-04 | 2021-08-30 | Dc Europa Ltd | Szerek glióma kezelésében történõ alkalmazásra |
| CN105017163A (zh) | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| AU2017204973A1 (en) | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| CN106432202B (zh) | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| KR102809395B1 (ko) | 2019-03-15 | 2025-05-16 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 암을 치료하기 위한 조성물 및 방법 |
| US20240058340A1 (en) | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061201A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| EP4405360A4 (en) | 2021-09-23 | 2025-08-20 | Erasca Inc | POLYMORPHIC FORMS OF EGFR INHIBITOR |
| WO2023244639A1 (en) | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
| WO2024081447A1 (en) | 2022-10-14 | 2024-04-18 | The Regents Of The University Of California | Egfr inhibitors for treating lung cancer |
| WO2024102177A1 (en) | 2022-11-08 | 2024-05-16 | The Regents Of The University Of California | Combination therapies for the treatment of brain cancer |
-
2022
- 2022-09-23 EP EP22873607.0A patent/EP4405360A4/en active Pending
- 2022-09-23 IL IL311616A patent/IL311616A/en unknown
- 2022-09-23 KR KR1020247013445A patent/KR20250005041A/ko active Pending
- 2022-09-23 CA CA3233057A patent/CA3233057A1/en active Pending
- 2022-09-23 WO PCT/US2022/044475 patent/WO2023049312A1/en not_active Ceased
- 2022-09-23 CN CN202280077001.9A patent/CN119343350A/zh active Pending
- 2022-09-23 AU AU2022350669A patent/AU2022350669A1/en active Pending
- 2022-09-23 JP JP2024518581A patent/JP2024535380A/ja active Pending
-
2024
- 2024-03-20 MX MX2024003495A patent/MX2024003495A/es unknown
- 2024-03-22 US US18/614,458 patent/US12545686B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024535380A5 (https=) | ||
| KR102522895B1 (ko) | Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법 | |
| JP2022176979A5 (https=) | ||
| CA2840721C (en) | Method of preparing modafinil polymorphic form i | |
| KR101391132B1 (ko) | 결정형 미노사이클린 염기 및 이의 제조방법 | |
| JP2018528199A5 (https=) | ||
| TWI682929B (zh) | 一種阿片樣物質受體（mor）激動劑的鹽、其富馬酸鹽i晶型及製備方法 | |
| EP2007758B1 (en) | A novel crystalline form of lamivudine | |
| CN111032634A (zh) | (s)-阿福拉纳的晶型 | |
| TW201900639A (zh) | 一種苯并呋喃類衍生物游離鹼的晶型及製備方法 | |
| EP2601175A1 (en) | A novel crystalline compound comprising saxagliptin and phosphoric acid | |
| CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
| CN107531744A (zh) | 一种奥贝胆酸的新结晶形式及其制备方法 | |
| CN102675395B (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
| WO2018103027A1 (zh) | 替吡法尼的晶型及其制备方法及药物组合物 | |
| JP2009531358A (ja) | 改良された結晶性物質 | |
| CN111194312A (zh) | 依地普仑的新盐和固态形式 | |
| US20090202647A1 (en) | Solid form of racemic rotigotine | |
| JP2023521631A5 (https=) | ||
| JP5468553B2 (ja) | 溶媒を本質的に含まないアバカビルの結晶形態 | |
| TW202014188A (zh) | 一種鴉片類物質受體激動劑的結晶形式及製備方法 | |
| KR100869017B1 (ko) | 페닐에탄올아민의 결정질 형태, 이의 제조 방법 및 이를포함하는 제약 조성물 | |
| WO2021119223A1 (en) | Solid state form of lemborexant | |
| JP2022538009A5 (https=) | ||
| KR102727487B1 (ko) | 트레프로스티닐 디에탄올아민염의 다형체 형태 b의 제조 방법 |